A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC)

Objective: Chimeric antigen receptor (CAR) T cell therapy has shown efficacy in leukemia. MUC16ecto is a tumor-associated antigen that is highly expressed in certain solid tumors, including high-grade serous ovarian cancer. We conducted a first-in human phase I dose escalating trial testing the safety of autologous 4H11-28z/fIL-12/EFGRt+ CAR T cells in patients with recurrent MUC16ecto+ HGSOC (NCT02498912). We incorporated regional intraperitoneal (IP) and intravenous (IV) delivery of the cells.